Choroidal thickness in diabetic retinopathy: The influence of antiangiogenic therapy

Retina

Volumn 34, Issue 6, 2014, Pages 1199-1207

  Laíns, Inês ^a   Figueira, João ^a,b,c,d   Santos, Ana Rita ^b,c   Baltar, Alda ^a   Costa, Miguel ^b   Nunes, Sandrina ^b   Farinha, Cláudia ^a   Pinto, Rita ^e   Henriques, José ^e   Silva, Rufino ^a,b,c,d  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^c Espaço Médico de Coimbra EMC   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e Instituto Cardiovascular de Lisboa   (Portugal)

Author keywords

Antiangiogenic agents; Choroid; Diabetes mellitus; Diabetic retinopathy; Macular edema; Optical coherence tomography; Photocoagulation; Retina

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; B SCAN; CENTRAL RETINAL THICKNESS; CHOROID; CHOROIDAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EXPLORATORY RESEARCH; FEMALE; HUMAN; LASER COAGULATION; MALE; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; PANRETINAL PHOTOCOAGULATION; PROLIFERATIVE NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

AGED; ANGIOGENESIS INHIBITORS; CHOROID; CROSS-SECTIONAL STUDIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901633981     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000053     Document Type: Article

References (33)

1. Ruta LM, Magliano DJ, Lemesurier R, et al. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med 2013;30:387-398
2. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol 2012;60: 428-431
3. Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 1975;59:649-656
4. Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol 1998;116:589-597. (Pubitemid 28414572
5. Esmaeelpour M, Považay B, Hermann B, et al. Mapping choroidal and retinal thickness variation in type 2 diabetes using three-dimensional 1060-nm optical coherence tomography. Invest Ophthalmol Vis Sci 2011;52:5311-5316
6. Querques G, Lattanzio R, Querques L, et al. Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci 2012;53:6017-6024
7. Regatieri CV, Branchini L, Carmody J, et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina 2012; 32:563-568
8. Vujosevic S, Martini F, Cavarzeran F, et al. Macular and peripapillary choroidal thickness in diabetic patients. Retina 2012; 32:1781-1790
9. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008;146:496-500
10. Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review. BMJ 2012;345:e5182
11. Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol 2011;89:405-411
12. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266. (Pubitemid 350211535
13. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85:425-430. (Pubitemid 47542265
14. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818
15. Regatieri CV, Branchini L, Fujimoto JG, Duker JS. Choroidal imaging using spectral-domain optical coherence tomography. Retina 2012;32:865-876
16. Maharaj ASR, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74:100-113. (Pubitemid 350051021
17. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006;47:3135-3142. (Pubitemid 351639793
18. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451-1459. (Pubitemid 41541430
19. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155:421-428. (Pubitemid 29370392
20. Tilton RG, Chang KC, LeJeune WS, et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999;40: 689-696. (Pubitemid 29109447
21. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48: 2814-2823. (Pubitemid 351261238
22. Shimomura Y, Hirata A, Ishikawa S, Okinami S. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2009; 247:1089-1094
23. Schraermeyer U, Julien S. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 2012;250:1303-1313
24. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 2012;119:1621-1627
25. Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 2012;6:837-844
26. Sayanagi K, Jo Y, Ikuno Y. Transient choroidal thinning after intravitreal bevacizumab injection for myopic choroidal neovascularization. J Clin Exp Ophthalmol 2011;2:2-6
27. Mainster MA. Decreasing retinal photocoagulation damage: Principles and techniques. Semin Ophthalmol 1999; 14:200-209. (Pubitemid 30061162
28. Stitt AW, Gardiner TA, Archer DB. Retinal and choroidal responses to panretinal photocoagulation: An ultrastructural perspective. Graefes Arch Clin Exp Ophthalmol 1995;233:699-705
29. Flower RW, Fryczkowski AW, McLeod DS. Variability in choriocapillaris blood flow distribution. Invest Opthalmol Vis Sci 1995;36:1247-1258
30. Takahashi A, Nagaoka T, Sato E, Yoshida A. Effect of panretinal photocoagulation on choroidal circulation in the foveal region in patients with severe diabetic retinopathy. Br J Ophthalmol 2008;92:1369-1373
31. Nonaka A, Kiryu J, Tsujikawa A, et al. Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina. Invest Ophthalmol Vis Sci 2002;43: 1204-1209. (Pubitemid 34258294
32. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologica 2007;221:95-102. (Pubitemid 46465434
33. Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: A systematic review. Br J Ophthalmol 2012;96: 167-178.